Starship megarocket blows up over Indian Ocean in latest bumpy test
[SOUTH PADRE ISLAND, United States] SpaceX's prototype Starship exploded over the Indian Ocean on Tuesday, capping another bumpy test flight for the rocket central to billionaire Elon Musk's dream of colonising Mars.
The biggest and most powerful launch vehicle ever built lifted off around 6.36 pm (2336 GMT) from the company's Starbase facility, near a southern Texas village that earlier this month voted to become a city - also named Starbase.
Excitement ran high among SpaceX engineers and spectators alike, after the last two outings ended with the upper stage disintegrating in fiery cascades over the Caribbean.
But signs of trouble emerged quickly: the first-stage Super Heavy booster blew up instead of executing its planned splashdown in the Gulf of Mexico.
A live feed then showed the upper-stage spaceship failing to open its doors to deploy a payload of Starlink satellite 'simulators.'
Though the ship flew farther than on its two previous attempts, it sprang leaks and began spinning out of control as it coasted through space.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
Mission teams vented fuel to reduce the force of the expected explosion, and onboard cameras cut out roughly 45 minutes into what was meant to be a 66-minute flight -- falling short of its target splashdown zone off Australia's west coast.
'Starship experienced a rapid unscheduled disassembly,' SpaceX posted on X - a familiar euphemism for fiery failure - while stressing it would learn from the setback.
Musk, meanwhile, vowed to pick up the pace: 'Launch cadence for the next 3 flights will be faster - approximately one every 3 to 4 weeks,' he said.
He did not say, however, whether he still planned to deliver a live stream about Mars that SpaceX had been promoting.
Space fans
Standing 403 feet (123 meters) tall, the black-and-white behemoth is designed to eventually be fully reusable and launch at low cost, carrying Musk's hopes of making humanity a multi-planetary species.
NASA is also counting on a variant of Starship to serve as the crew lander for Artemis 3, the mission to return Americans to the Moon.
Ahead of the launch, dozens of space fans gathered at Isla Blanca Park on nearby South Padre Island, hoping to catch a glimpse of history.
Several small tourist boats also dotted the lagoon, while a live feed showed Musk sitting at ground control in Starbase, wearing an 'Occupy Mars' T-shirt.
Australian Piers Dawson, 50, told AFP he's 'obsessed' with the rocket and built his family vacation around the launch - his first trip to the United States, with his wife and teenage son whom he took out of school to be there.
'I know in science there's never a failure, you learn everything from every single test so that was still super exciting to see,' said Joshua Wingate, a 33-year-old tech entrepreneur from Austin, after the launch.
'Fail fast, learn fast'
Starship has now completed nine integrated test flights atop its Super Heavy booster.
SpaceX is betting that its 'fail fast, learn fast' ethos, which helped it dominate commercial spaceflight, will once again pay off.
One bright spot: the company has now caught the Super Heavy booster in the launch tower's giant robotic arms three times - a daring engineering feat it sees as key to rapid reusability and slashing costs.
This ninth flight marked the first time SpaceX reused a Super Heavy booster, though it opted not to attempt a catch - instead pushing the envelope with a steeper descent angle and one engine intentionally disabled.
The FAA recently approved an increase in Starship launches from five to 25 annually, stating the expanded schedule wouldn't harm the environment -- a decision that overruled objections from conservation groups concerned about impacts to sea turtles and shorebirds. AFP
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
15 hours ago
- Straits Times
Japan's ispace counts down to second moon-landing attempt on June 6
A SpaceX Falcon 9 rocket launches carrying Firefly Aerospace's Blue Ghost lunar lander as the primary payload and Japan-based ispace's Resilience lander as a secondary payload, from Kennedy Space Center in Cape Canaveral on Jan 15. PHOTO: REUTERS Japan's ispace counts down to second moon-landing attempt on June 6 TOKYO - Japanese startup ispace aims to become the first non-US company to achieve a controlled moon landing as it prepares for the touchdown of its second uncrewed spacecraft on June 6, two years after its inaugural mission ended in failure. Tokyo-based ispace hopes to join US firms Intuitive Machines and Firefly Aerospace, which have accomplished commercial landings since 2024 amid an intensifying global race for the moon that includes state-run missions from China and India. The mission also highlights broad public- and private-sector expectations from Japan, which remains committed to lunar exploration as part of Nasa's Artemis moon programme, despite mounting uncertainty about its future as President Donald Trump reshapes US space policies. "A moon landing is not a dream but it has become a reality," ispace CEO Takeshi Hakamada has said. The company's first lunar lander in April 2023 crashed onto the moon's surface due to a software issue that incorrectly assessed its altitude during descent over precipitous terrain. Its second lander, named Resilience, in January shared a SpaceX rocket launch with Firefly's Blue Ghost lander. Blue Ghost took a faster trajectory to the moon and touched down successfully in March. Currently circling about 100km above the lunar surface, Resilience carries a rover built by ispace's Luxembourg subsidiary and payloads worth a total of US$16 million (S$20.57 million), including scientific instruments from Japanese firms and a Taiwanese university. After June 6's landing on Mare Frigoris, a lunar sea relatively close to the moon's north pole, scheduled for 4.17am Japan time (3.17am Singapore time), the 2.3m high lander and the microwave-sized rover are tasked to capture images of regolith, the moon's fine-grained surface material. If successful, ispace said it will transfer the ownership of the collected material to Nasa to fulfil what it says would be the world's first commercial transaction of lunar resources. According to a 2020 Nasa statement, ispace's Japan and Luxembourg units would each receive US$5,000 under this arrangement. Nasa was not immediately able to comment on the impact of the Trump administration's proposed budget reductions on the contract. An ispace spokesperson declined to comment. Japan's lunar enthusiasm The company envisions establishing a lunar colony of 1,000 inhabitants by the 2040s, tapping the moon's water resources. It plans seven more missions in the US and Japan through 2029, including a Nasa-sponsored one as part of the Artemis programme, to capitalise on increasing demands for lunar transportation. About a dozen corporate partners have provided support for ispace missions, including titanium materials from Citizen Watch and design expertise from automaker Suzuki. In Japan, a wide range of businesses from construction firms to carmakers engage in lunar exploration research, and the breadth of industrial interest in the moon may surpass that in the United States, said Atsushi Uchida, Research Director at Mitsubishi Research Institute. The government has been keen to promote Japan's roles in the Artemis programme, signing an agreement with Nasa in 2024 to include two Japanese astronauts and a Toyota-built rover in forthcoming missions to the lunar surface. Exploration of the moon and Mars is one of the key objectives of Japan's newly-established multibillion-dollar space venture fund. "Having ispace, a domestic transportation option, is a huge advantage for Japanese businesses and universities that foray into lunar exploration using government funds," said Ritsumeikan University professor Kazuto Saiki, who participated in Japan Aerospace Exploration Agency's (Jaxa) Slim mission that achieved Japan's first lunar landing last year. Jaxa President Hiroshi Yamakawa said in May that he was rooting for ispace's re-attempt because their "success will attract attention to the whole Japanese space industry." Investors are keen. Shares in ispace, which made a blistering market debut in 2023 but languished after the landing failure, have risen about 60 per cent year-to-date, epitomising a space startup boom in the Japanese capital market. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
Straits Times
a day ago
- Straits Times
From no hope to a potential cure for a deadly blood cancer
The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. PHOTO: UNSPLASH From no hope to a potential cure for a deadly blood cancer NEW YORK - A group of 97 patients had long-standing multiple myeloma, a common blood cancer that doctors consider incurable, and faced a certain, and extremely painful, death within about a year. They had gone through a series of treatments, each of which controlled their disease for a while. But then it came back, as it always does. They reached the stage where they had no more options and were facing hospice. They all got immunotherapy, in a study that was a last-ditch effort. A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. And after five years, it still has not returned in those patients – a result never before seen in this disease. These results, in patients whose situation had seemed hopeless, has led some battle-worn American oncologists to dare to say the words 'potential cure.' 'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr Norman Sharpless, a former director of the National Cancer Institute who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.' The new study, reported on June 3 at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which has an exclusive licensing agreement with Legend Biotech. The 36,000 Americans who develop multiple myeloma each year face an illness that eats away at bones, so it looks as if holes have been punched out in them, said Dr Carl June, of the University of Pennsylvania. Bones collapse. Dr June has seen patients who lost 6 inches (15.24cm) in height. 'It's a horrible, horrible death,' Dr June said. 'Right now advanced myeloma is a death sentence.' (Dr June has immunotherapy patents that are owned by his university.) There have been treatment advances that increased median survival from two years to 10 over the past two decades. But no cures. Dr Peter Voorhees of the Atrium Health Levine Cancer Institute in North Carolina and the Wake Forest University School of Medicine, who is lead researcher for the newly published study, said patients usually go through treatment after treatment until, ultimately, the cancer prevails, developing resistance to every class of drug. They end up with nothing left to try. The Legend immunotherapy is a type known as CAR-T. It is delivered as an infusion of the patient's own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionised prospects for patients with other types of blood cancer, like leukaemia. Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it can have severe side effects including a high fever, trouble breathing and infections. Patients can be hospitalised for weeks after receiving it. But Legend managed to develop one that works in multiple myeloma, defying sceptics. The Chinese company gained attention for its CAR-T eight years ago when it made extravagant claims, which were met by snickers from American researchers. Johnson & Johnson, though, was looking for a CAR-T to call its own. So, said Mr Mark Wildgust, an executive in the oncology section of the American drug giant, the company sent scientists and physicians to China to see if the claims were true. 'We went site by site to look at the results,' he said. The company was convinced. It initiated a collaboration with Legend and began testing the treatment in patients whose myeloma had overcome at least one standard treatment. Compared with patients who had standard treatment, those who had the immunotherapy lived longer without their disease progressing. The immunotherapy received regulatory approval in that limited setting and is sold under the brand name Carvykti. The study did not determine whether this difficult treatment saved lives. The new study took on a different challenge – helping patients at the end of the line after years of treatments. Their immune systems were worn down. They were, as oncologists said, 'heavily pretreated.' So even though CAR-T is designed to spur their immune systems to fight their cancer, it was not clear their immune systems were up to it. Oncologists say that even though most patients did not clear their cancer, having a third who did was remarkable. To see what the expected life span would be for these patients without the immunotherapy, Johnson & Johnson looked at data from patients in a registry who were like the ones in its study – they had failed every treatment. They lived about a year. For Ms Anne Stovell of New York, one of the study patients whose cancer disappeared, the result is almost too good to be true. She says she went through nine drugs to control her cancer after it was diagnosed in 2010, some of which had horrendous side effects. Each eventually failed. Taking the Legend CAR-T was difficult – she said she had spent nearly three weeks in the hospital. But since that treatment six years ago, she has no sign of cancer. She said it was still difficult for her to believe her myeloma is gone. A new ache – or an old one – can bring on the fear. 'There's that little seed of doubt,' she said. But in test after test, the cancer has not reappeared. 'It's a relief for me every year to get a bone marrow biopsy,' she said. Myeloma experts applauded the results. Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are 'hideously expensive,' Dr June said, costing more than US$100,000 (S$129,143) a year. The total cost over the years can be millions of dollars, Dr June said, usually paid by insurers, 'and it doesn't even cure you.' CAR-T is expensive too. Carvykti's list price is US$555,310. But it is a one-time treatment. And, more important, the hope is that perhaps by giving it earlier in the course of the disease, it could cure patients early on. Johnson & Johnson is now testing that idea. Dr Kenneth Anderson, a myeloma expert at Dana-Farber Cancer Institute who was not involved with the study, said that if the treatment is used as a first-line treatment, 'cure is now our realistic expectation.' That, at least, is the hope, Dr Sharpless said. And for those like the patients in the new study who are living at least five years – so far – without disease, the outcome 'really is eye-popping,' Dr Sharpless said. 'That's getting to a point where you wonder if it will ever come back,' he added. NYTIMES Join ST's Telegram channel and get the latest breaking news delivered to you.
CNA
2 days ago
- CNA
Elon Musk projects SpaceX revenue of about $15.5 billion in 2025
Elon Musk's SpaceX will record revenue of about $15.5 billion this year, the billionaire said on Tuesday, underscoring the rocket maker's growing dominance in the commercial space sector. The company's commercial revenue from space will exceed NASA's budget of roughly $1.1 billion next year, Musk said in a post on X. While NASA continues to fund deep space exploration and research missions, SpaceX has leaned on growing demand for cost-effective launch services and satellite communications to generate revenue. The company is developing a 400-foot (122-meter) tall Starship rocket system, which the world's richest person has said will play a crucial part in sending humans to Mars. The company's reusable Falcon 9 and Falcon Heavy rockets have significantly reduced launch costs, enabling SpaceX to secure a substantial share of the global launch market. In 2024, SpaceX achieved a record-breaking year with 134 Falcon launches, making it the most active launch operator globally. SpaceX is targeting to beat that record with 170 launches by the end of the year, the company said last week, as it attempts to meet growing demand for satellite deployment. Still, SpaceX's revenue is driven largely by its satellite internet service, Starlink, which Musk has said will go public, but has not provided a timeline. In early November 2023, Musk reported that Starlink had achieved breakeven cashflow. Under the Starlink banner, SpaceX has deployed thousands of satellites to deliver broadband internet globally. SpaceX and two partners have emerged as frontrunners to win a crucial part of U.S. President Donald Trump's "Golden Dome" missile defense shield, Reuters reported in April, citing six people familiar with the matter.
